| abstract |
The invention thus relates to recombinant, defective viral salts comprising at least one heterologous gene under the control of a glucose-inducible expression signal. In one embodiment of the invention, a gene encoding azinylline, or a variant thereof, as a heterologous therapeutic gene is introduced into a suitable tissue or cell, and the gene encoding the glucose-sensitive L-form pyruvate kinase is placed under the primer or part of this primer. Adenovirus viruses or retrovirus viruses commonly used in gene therapy are used as vectors for carrying out the invention. The invention relates to pharmaceutical compositions comprising these viral vectors. ŕ |